LT2346994T - Knock-in pelė, skirta chimerinių antikūnų gamybai - Google Patents

Knock-in pelė, skirta chimerinių antikūnų gamybai

Info

Publication number
LT2346994T
LT2346994T LTEPPCT/US2009/059131T LT09059131T LT2346994T LT 2346994 T LT2346994 T LT 2346994T LT 09059131 T LT09059131 T LT 09059131T LT 2346994 T LT2346994 T LT 2346994T
Authority
LT
Lithuania
Prior art keywords
knock
mice
production
chimeric antibodies
chimeric
Prior art date
Application number
LTEPPCT/US2009/059131T
Other languages
English (en)
Inventor
Larry Green
Hiroaki Shizuya
Original Assignee
Ablexis, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablexis, Llc filed Critical Ablexis, Llc
Publication of LT2346994T publication Critical patent/LT2346994T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEPPCT/US2009/059131T 2008-09-30 2009-09-30 Knock-in pelė, skirta chimerinių antikūnų gamybai LT2346994T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10159708P 2008-09-30 2008-09-30
US10193808P 2008-10-01 2008-10-01
PCT/US2009/059131 WO2010039900A2 (en) 2008-09-30 2009-09-30 Non-human mammals for the production of chimeric antibodies

Publications (1)

Publication Number Publication Date
LT2346994T true LT2346994T (lt) 2022-03-10

Family

ID=42074200

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2009/059131T LT2346994T (lt) 2008-09-30 2009-09-30 Knock-in pelė, skirta chimerinių antikūnų gamybai

Country Status (11)

Country Link
US (8) US9346873B2 (lt)
EP (2) EP3889265A1 (lt)
KR (3) KR101826224B1 (lt)
AU (1) AU2009298458B2 (lt)
CA (2) CA3038954A1 (lt)
DK (1) DK2346994T3 (lt)
ES (1) ES2908040T3 (lt)
LT (1) LT2346994T (lt)
NZ (1) NZ592308A (lt)
PL (1) PL2346994T3 (lt)
WO (1) WO2010039900A2 (lt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592308A (en) 2008-09-30 2012-11-30 Ablexis Llc Non-human mammals for the production of chimeric antibodies
DK2798950T4 (da) 2009-07-08 2023-05-15 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
EP2501817B2 (en) 2010-02-08 2021-04-21 Regeneron Pharmaceuticals, Inc. Common light chain mouse
LT3248462T (lt) 2010-03-31 2024-05-27 Ablexis, Llc Pelių genų inžinerija, skirta chimerinių antikūnų gamybai
EP2582230A1 (en) 2010-06-17 2013-04-24 Kymab Limited Animal models and therapeutic molecules
MX348942B (es) * 2010-06-22 2017-07-04 Regeneron Pharma Ratones que expresan una cadena ligera hibrida de inmunoglobulina.
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
AU2011285919C1 (en) 2010-08-02 2015-09-17 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising VL domains
ES2805364T3 (es) 2011-02-25 2021-02-11 Regeneron Pharma Ratones ADAM6
WO2012122484A1 (en) 2011-03-09 2012-09-13 Roberto Polakiewicz Methods and reagents for creating monoclonal antibodies
JP6510234B2 (ja) 2011-08-05 2019-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化ユニバーサル軽鎖マウス
JP2014533930A (ja) 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
WO2013045916A1 (en) * 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
PL3216871T3 (pl) 2011-10-17 2022-03-21 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
JP6327750B2 (ja) 2011-12-20 2018-05-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化軽鎖マウス
SG11201405164QA (en) 2012-03-16 2014-10-30 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
DK2825036T3 (en) 2012-03-16 2018-07-16 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified rodents to generate them
RU2018128915A (ru) 2012-03-16 2019-02-18 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К рН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
WO2013144567A1 (en) 2012-03-28 2013-10-03 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP2858487B1 (en) 2012-06-12 2019-10-23 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
JP6426606B2 (ja) * 2012-08-03 2018-11-21 エスエービー，エルエルシー トランスジェニック動物におけるヒト抗体産生のための複合染色体工学
US9848587B2 (en) * 2013-02-20 2017-12-26 Regeneron Pharmaceuticals, Inc. Humanized T cell co-receptor mice
CN109769752A (zh) 2013-02-20 2019-05-21 瑞泽恩制药公司 具有修饰的免疫球蛋白重链序列的非人类动物
ES2949029T3 (es) * 2013-02-22 2023-09-25 Regeneron Pharma Células murinas que expresan complejo mayor de histocompatibilidad humanizado
CN108464278B (zh) * 2013-03-11 2021-05-04 瑞泽恩制药公司 表达嵌合的主要组织相容性复合物(mhc)ii类分子的转基因小鼠
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
EP3092007A4 (en) * 2014-01-10 2017-06-07 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CN107529739B (zh) * 2015-04-30 2021-01-08 株式会社特殊免疫研究所 表达人特定分子和人Fcγ受体家族的转基因非人动物
KR20180038554A (ko) * 2015-08-27 2018-04-16 크리스탈 바이오사이언스 주식회사 공통 경쇄를 갖는 항체 생산을 위한 유전자도입 동물
EP3384030A4 (en) * 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
CA3012833A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
HUE061619T2 (hu) 2016-06-03 2023-07-28 Regeneron Pharma Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
EP3766343B1 (en) 2016-11-04 2022-05-11 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
HUE060608T2 (hu) 2017-12-05 2023-03-28 Regeneron Pharma Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása
KR20200135397A (ko) 2018-03-24 2020-12-02 리제너론 파마슈티칼스 인코포레이티드 펩티드-mhc 복합체에 대한 치료 항체를 생성하기 위한 유전적으로 변형된 비인간 동물, 이의 제조 방법
EP4023059A1 (en) 2018-06-14 2022-07-06 Regeneron Pharmaceuticals, Inc. Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
MA56117A (fr) 2019-06-05 2022-04-13 Regeneron Pharma Animaux non humains ayant un répertoire de chaînes légères lambda limité exprimé à partir du locus kappa et leurs utilisations
US20220409732A1 (en) 2019-12-02 2022-12-29 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
JP2023554382A (ja) 2020-12-16 2023-12-27 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
IL303868A (en) 2020-12-23 2023-08-01 Regeneron Pharma Nucleic acids encoding anchor-modified antibodies and uses thereof
PE20241357A1 (es) 2021-04-22 2024-07-03 Astellas Pharma Inc Anticuerpo biespecifico anti-cldn4/anti-cd137
WO2023250388A1 (en) 2022-06-22 2023-12-28 Voyager Therapeutics, Inc. Tau binding compounds
WO2024092038A2 (en) 2022-10-25 2024-05-02 Ablexis, Llc Anti-cd3 antibodies
WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US623010A (en) * 1899-04-11 greenhow
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1990000616A1 (en) 1988-07-07 1990-01-25 Michael Neumaier Recombinomas
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6689610B1 (en) * 1989-08-22 2004-02-10 University Of Utah Research Foundation Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ES2087997T3 (es) * 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2084774A1 (en) 1990-06-12 1991-12-13 Allan Bradley Method for homologous recombination in animal and plant cells
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) * 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1992015694A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
GB9119338D0 (en) * 1991-09-10 1991-10-23 Inst Of Animal Physiology And Control of gene expression
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE4228162C1 (de) * 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
CZ293355B6 (cs) * 1997-03-14 2004-04-14 Idec Pharmaceuticals Corporation Způsob integrace genů do specifických míst genomu savčí buňky homologní rekombinací a příslušné vektorové systémy
US6774279B2 (en) * 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6090554A (en) * 1997-10-31 2000-07-18 Amgen, Inc. Efficient construction of gene targeting vectors
GB9823930D0 (en) * 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
AU1456101A (en) * 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
DE60138273D1 (de) * 2000-04-12 2009-05-20 Dana Farber Cancer Inst Inc Selbstlöschende rekombinasen, dafür kodierende nukleinsäuren und verfahren zu deren verwendung
MXPA03001915A (es) * 2000-08-03 2004-09-10 Therapeutic Human Polyclonals Produccion de anticuerpos humanizados en animales transgenicos.
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US7105348B2 (en) * 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI313299B (en) * 2000-11-30 2009-08-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1440146A4 (en) 2001-06-26 2005-06-22 Genome Biosciences Llc PROCESS AND VECTORS FOR THE TARGETING OF GENES
CN1671416B (zh) * 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
WO2003027261A2 (en) 2001-09-27 2003-04-03 Functional Genetics, Inc. Methods and compositions for gene targeting by homologous recombination
EP2319301B1 (en) * 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
CN1500141A (zh) 2001-12-04 2004-05-26 �Ϻ���ͨ��ѧ 基因靶向方法和载体
JP3743394B2 (ja) * 2002-05-31 2006-02-08 株式会社村田製作所 赤外線センサおよびそれを用いた電子装置
TW588243B (en) * 2002-07-31 2004-05-21 Trek 2000 Int Ltd System and method for authentication
US20040128703A1 (en) * 2002-09-09 2004-07-01 Hiroaki Shizuya Methods and compositions for the generation of humanized mice
JP4324375B2 (ja) * 2002-12-27 2009-09-02 ユニ・チャーム株式会社 圧縮溝と可撓部とを備えた吸収性物品
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
CA2517519A1 (en) * 2003-03-04 2004-09-16 Alexion Pharmaceuticals, Inc. Vectors used to create hybrid constant regions
WO2005001087A2 (en) * 2003-06-11 2005-01-06 Regeneron Pharmaceuticals, Inc. Methods of modifying genes in eukaryotic cells
US20050153392A1 (en) 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
FR2861255B1 (fr) * 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
US7362911B1 (en) * 2003-11-13 2008-04-22 Pixim, Inc. Removal of stationary noise pattern from digital images
SI2383295T1 (sl) * 2003-12-10 2015-07-31 E.R. Squibb & Sons, L.L.C. Protitelesa IP-10 in njihova uporaba
DE102004036249A1 (de) * 2004-07-26 2006-02-16 Bayer Materialscience Ag Formkörper mit hoher Lichtstreuung und hoher Lichttransmission
CN101084317A (zh) 2004-10-22 2007-12-05 人类多克隆治疗公司 对内源免疫球蛋白表达的抑制
WO2006072803A2 (en) 2005-01-10 2006-07-13 Medical Research Council Antibody
CA2604440A1 (en) * 2005-04-29 2006-11-09 Inserm (Institut De La Sante Et De La Recherche Medicale) Transgenic animals and methods of making recombinant antibodies
US7698703B2 (en) * 2005-06-29 2010-04-13 Gemalto Inc. Imparting digital uniqueness to the types of a programming language using a unique digital sequence
BRPI0615026A8 (pt) 2005-08-19 2018-03-06 Abbott Lab imunoglobulina de domínio variável duplo e seus usos
CA2638774C (en) * 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
WO2008027986A2 (en) 2006-09-01 2008-03-06 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
WO2008090958A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
GB0707326D0 (en) * 2007-04-16 2007-05-23 Avilion Ltd Diverter valve
PT2152880E (pt) 2007-06-01 2011-12-15 Omt Inc Composições e métodos para inibição de genes de imunoglobulinas endógenas e produção de anticorpos idiótipos humanos transgénicos
NZ589411A (en) 2008-05-23 2013-01-25 Ablexis Llc Method of generating single vl domain antibodies in transgenic animals
DK2147594T3 (da) 2008-06-27 2014-02-10 Merus B V Antistofproducerende ikke-humane pattedyr
CN102164676B (zh) 2008-07-10 2014-10-29 菲活机器制造公司 带有分离器的珠磨机
NZ592308A (en) 2008-09-30 2012-11-30 Ablexis Llc Non-human mammals for the production of chimeric antibodies
RU2011129459A (ru) 2008-12-18 2013-01-27 Эрасмус Юниверсити Медикал Сентр Роттердам Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
DK2798950T4 (da) 2009-07-08 2023-05-15 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
MY173363A (en) * 2009-12-10 2020-01-21 Regeneron Pharma Mice that make heavy chain antibodies
LT3248462T (lt) 2010-03-31 2024-05-27 Ablexis, Llc Pelių genų inžinerija, skirta chimerinių antikūnų gamybai
EP2582230A1 (en) 2010-06-17 2013-04-24 Kymab Limited Animal models and therapeutic molecules
MX348942B (es) 2010-06-22 2017-07-04 Regeneron Pharma Ratones que expresan una cadena ligera hibrida de inmunoglobulina.

Also Published As

Publication number Publication date
DK2346994T3 (da) 2022-02-28
EP2346994A2 (en) 2011-07-27
US20160222091A1 (en) 2016-08-04
KR20190065477A (ko) 2019-06-11
EP3889265A1 (en) 2021-10-06
AU2009298458B2 (en) 2015-10-08
KR101987351B1 (ko) 2019-06-10
US10575504B2 (en) 2020-03-03
CA2739038A1 (en) 2010-04-08
KR101826224B1 (ko) 2018-02-06
CA2739038C (en) 2020-04-28
US20160219848A1 (en) 2016-08-04
US20160222090A1 (en) 2016-08-04
PL2346994T3 (pl) 2022-04-19
KR20110089846A (ko) 2011-08-09
ES2908040T3 (es) 2022-04-27
US10561123B2 (en) 2020-02-18
CA3038954A1 (en) 2010-04-08
US20160222093A1 (en) 2016-08-04
KR20180014862A (ko) 2018-02-09
US10492476B2 (en) 2019-12-03
US20160219850A1 (en) 2016-08-04
WO2010039900A2 (en) 2010-04-08
US10555506B2 (en) 2020-02-11
KR102362774B1 (ko) 2022-02-15
WO2010039900A3 (en) 2011-03-03
US20160222092A1 (en) 2016-08-04
US20110236378A1 (en) 2011-09-29
EP2346994A4 (en) 2012-03-14
AU2009298458A1 (en) 2010-04-08
NZ592308A (en) 2012-11-30
US20160219849A1 (en) 2016-08-04
EP2346994B1 (en) 2022-02-16
US9346873B2 (en) 2016-05-24
US10638736B2 (en) 2020-05-05

Similar Documents

Publication Publication Date Title
PL2346994T3 (pl) Myszy knock-in do wytwarzania chimerycznych przeciwciał
IL261257B (en) Mice with human cγr
LT3251503T (lt) Pelės genų inžinerija, siekiant produkuoti chimerinius antikūnus
IL217381A0 (en) Optimizing the production of antibodies
IL229512A (en) Anti-vegf antibodies
ZA201005348B (en) Humanized anti-c5ar antibodies
EP2181121A4 (en) CHIMÄRE ANTIGENE
SI2406284T1 (sl) Anti-bcma protitelesa
GB0920127D0 (en) Antibodies
EP2464220A4 (en) Transgenic animal for the production of antibodies with minimal complementarity-determining regions
GB0909906D0 (en) Antibodies
EP2262831A4 (en) ANTI-properdin antibody
IL217919A0 (en) Humanized anti-cdcp1 antibodies
EP2259795A4 (en) ANTI-VEGF ANTIBODY
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
GB0821100D0 (en) Antibodies
EP2445513A4 (en) CHIMEROUS FACTOR VII MOLECULES
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
IL207581A0 (en) Anti-tyrp1 antibodies
ZA201104394B (en) Process for the manufacture of vinyl acetate
GB0818356D0 (en) Antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
EP2424892A4 (en) DC-STAMP ANTIBODY
GB0820307D0 (en) Antibody production
GB0815963D0 (en) Antibody production